Webinar

The role of AI in predicting stem cell donor availability

For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection.  Our expert panel will explain how to: Predict an…

Case Study

How Cell Therapy Clinical Trials Can Save Time and Cost

A client initiated a Phase I clinical trial for its allogeneic cell therapy. Several months in, limited success recruiting patients had led to an expensive lack of progress. The client engaged with the CIBMTR® Bioinformatics Consulting team through NMDP BioTherapies℠ to identify U.S. states and counties with the highest density of patients and donors with…

Webinar

How Patient Focus Drives Clinical Trial Results: The Intersection of Sponsor, CRO, Site and Patient.

Clinical trial sponsors and CROs have compelling reasons to design an effective clinical trial. You need to not only to answer your research question but also mitigate budget pressures and quickly bring a product to market that addresses patients’ chief complaints. In this webinar you’ll walk away with a better understanding of: Why the voice…

Webinar

Leveraging the Experience of Cord Blood Banking in Development of Cellular Therapies

Along with gaining insights into how to tap into the expertise of cord blood banks and access therapy-matched cord blood units (CBUs), you’ll get a better understanding of: Comprehensive benefits of cord blood as an allogeneic cell source for cellular therapy Characteristics and attributes of the existing cord blood inventory Importance of managing logistics for…

Clinical Trials Support

Comprehensive Clinical Trial Support

Cell therapy clinical trials—including those for hematopoietic cell transplantation (HCT)—come with unique challenges and complexity that impact the clinical trial sponsor, investigators, clinical trial sites, physicians, and patients and their caregivers. We offer comprehensive clinical trial services for academic and industry investigators and sponsors, as well as patients, because we know saving more lives through…

Webinar

Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All

Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of:  Efficiencies in donor selection to reduce uncertainties about HLA matching and improve patient outcomes  HLA complexity in cell source selection  How machine…

Webinar

Navigating Scalability and Consistency in the Allogeneic Supply Chain

Watch this on-demand webinar for an in-depth discussion on these questions and more. You’ll walk away with insights on navigating the scalability of donor starting material as the allogeneic cell therapy industry grows. PANELISTS Abby Waters, PhD Senior Manager, Solutions Owner NMDP BioTherapies℠ Dean A. Lee, MD, PhD Physician, Hematology and Oncology Director of the…

Webinar

International Differences in Cellular Starting Material Quality and Regulatory Requirements

Navigating international regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where they diverge.…